The concept of endocrine disruption emerged over a decade ago with the observation that several natural or industrial compounds can interfere with estrogen and androgen signaling, and thereby affect both male and female reproductive functions. Since then, many endocrine-disrupting chemicals (EDCs) have been identified and the concept has been broadened to receptors regulating other aspects of endocrine pathways. In that context, interference of EDCs with receptors regulating metabolism has been proposed as a factor that could contribute to metabolic diseases such as obesity and diabetes. We review recent studies showing that several pollutants, including phthalates and organotins, interfere with PPAR (peroxisome proliferator-activated receptors) nuclear receptors and may thereby affect metabolic homeostasis. Particular emphasis is given on the mechanisms of action of these compounds. However, unlike what has been suspected, we provide evidence from mouse models suggesting that in utero exposure to the phthalate ester di-ethyl-hexyl-phthalate most likely does not predispose to obesity. Collectively, these studies define a subclass of EDCs that perturb metabolic signaling and that we propose to define as metabolic disruptors.
Introduction
Endocrine-disrupting chemicals (EDCs) are compounds that modulate inappropriately the endocrine system and potentially induce adverse health effects in exposed individuals and populations. They have been defined by the European Commission as 'exogenous substances or mixtures, that alter function(s) of the endocrine system and consequently cause adverse health effects in an intact organism, its progeny or (sub)population'. 1 These xenobiotic chemicals and environmental contaminants interfere with the production, release, transport, metabolism, binding, action or elimination of natural hormones responsible for homeostasis and essential for normal growth and development. 2, 3 Some EDCs are naturally occurring, for instance the flavonoids found in fruits and vegetables, and others are end products or byproducts from medicinal or industrial chemistry. Several kinds of industrial chemicals are known as environmental contaminants and examples can be found among persistent organochlorine pollutants such as DDT (1,1,1-trichloro-2,2-bis(p-chlorophenyl)ethylene), and polychlorinated biphenyls. Pharmaceutical and agrochemicals are also a common source of EDCs, such as synthetic/natural steroid hormones and atrazine, found at significant levels in effluent wastewater. One major mode of action of EDCs seems to be the interference with gene expression programs regulated by nuclear receptors (NRs), a class of transcription factors that regulate gene expression programs in response to compounds acting as NR activators or antagonists. 4, 5 Most of the research on EDCs has, however, focused so far on their deleterious actions on sexual development and reproduction caused by interference with steroid signaling through the estrogen and/or androgen receptors, as the outcome is easily identifiable and represents a sensitive issue for a broad public. 6 However, EDCs may also affect other nuclear receptors, such as those involved in thyroid function or in lipid signaling. In addition, a current hypothesis is that some EDCs may act as 'obesogens', possibly contributing to the current epidemic of obesity. [7] [8] [9] [10] In this review we will focus on the endocrine disruption mediated by EDCs interacting with the lipid-activated nuclear receptors, peroxisome proliferator-activated receptors (PPARs) and their potential role as metabolic disruptors.
EDCs and obesity
Obesity is a growing concern worldwide as global obesity rates have risen dramatically in developed countries over the past three decades. Overweight and obesity are associated with a number of chronic diseases, including metabolic syndrome, atherosclerosis, cardiovascular complications and some forms of cancer. A well-documented fact is the dramatic increase of type 2 diabetes in young individuals, which parallels the increase in childhood obesity. It is mainly considered that modern lifestyle causes the rapid advance in obesity rates, with excessive energy intake and lack of physical activity playing prominent roles. In contrast, the role of genetic components is less clear. With the exception of specific instances of obesity arising from genetic causes, the pace of genetic changes at the population level is inadequate to explain the rapid increase in obesity rates in Western societies. Recent works suggests that several changes in the chemical environment over the past 40 years may play a role in the recent global obesity epidemic. [7] [8] [9] [10] These provocative hypotheses predict the existence of 'environmental obesogens', which disrupt or interfere with critical pathways involved in energy balance, adipogenesis and lipid metabolism. Hence, an exposure to EDCs in utero or during lifetime might predispose to or even cause obesity. With regard to the role of EDC exposure in utero, the correlation between prenatal maternal smoking and higher prevalence of obesity reported in a British adult population represents a proof-ofconcept. 11, 12 Along this line, Grun et al. 13 showed that organotins, a group of diverse and widely distributed environmental pollutants, promote adipogenesis in mouse models, with embryonic development representing a particularly critical period of exposure. These in vivo results support the Barker's hypothesis, 14 which postulates that in utero fetal nutritional status is a potential risk factor for metabolic diseases. Studies by Newbold et al. 15, 16 show that prenatal and postnatal exposure to diethylstilbestrol, a synthetic estrogen prescribed between 1940 and 1980s to pregnant women at risk of miscarriage, causes an initial body weight reduction of the exposed infant, followed by a 'catch-up' period around puberty, but finally results in a significant increase in adult body weight. These studies highlight the possible effects of perinatal exposure to EDCs, whereas other obesogen activities might occur upon chronic exposure during adult life. However, obesity is one end point of metabolic perturbations, which may themselves encompass a broader range of alterations. Thus, additional studies predicting the existence of other metabolic disruptors that might act on different molecular targets and cellular mechanisms open an exciting area of future research.
Phthalates and metabolic disruption
Since 1933, phthalate esters have been used worldwide as plasticizers and stabilizers in a variety of plastics and consumer goods. They are found in industrial paints and solvents but also in cosmetics, perfumes and medicines. Thus, nearly all groups of industrial consumer products contain phthalates or traces of phthalates. Although phthalates are nonpersistent chemicals that are rapidly metabolized, contamination of the environment is significant due to their widespread use. 17 Humans are exposed to phthalates through ingestion, inhalation or dermal absorption throughout their entire life. The long-branched di-ethyl-hexylphthalate (DEHP) is one of the most widespread phthalate plasticizers used as a major component in polyvinyl chloride plastics, which are frequently used in medical devices and consumer products. Other diester phthalates such as di-isononylphthalate, di-iso-decylphthalate, di-ethyl-phthalate, di-n-butyl phthalate, butyl benzyl phthalate and di-n-octyl phthalate are also widely used. Importantly, these compounds are incorporated to plastics noncovalently, which favors their leaching and the subsequent contamination of the environment.
Phthalates are generally metabolized in a two-phase process. In phase I, diesters phthalates are hydrolyzed into primaries metabolites monoesters phthalates, in a process catalyzed by lipases and esterases. For instance, upon ingestion, pancreatic lipases present in the intestine convert DEHP to its primary and active metabolite mono(2-ethylhexyl)phthalate (MEHP), which is preferentially absorbed by enterocytes. In addition, plasma and hepatic lipases can also produce MEHP from DEHP directly reaching the blood through absorption or medical contamination. 18 The phase II is a conjugation process that leads to the urinary excretion of the conjugated metabolite. Finally, because of the branched chain of DEHP, the metabolic pattern is capmlex and leads to several metabolites such as mono(2-ethyl-5-hydroxyhexyl)phthalate and mono (2-ethyl-5-oxohexyl)phthalate). Several studies show a correlation between phthalates and endocrine disorders. In short-and long-term rodent studies, dose-related adverse effects, such as deregulated levels of serum insulin, blood glucose, liver glycogen, T3, T4 and thyroid stimulating hormone as well as cortisol, were observed. 19, 20 Even more specifically, Stahlhut et al.
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showed that the log-transformed concentrations of several phthalate metabolites positively correlated with abdominal obesity and insulin resistance in adult US males.
The Nuclear receptor superfamily and endocrine disruption
As mentioned in the introduction, one main mechanism of endocrine disruption occurs through interference with the hormonal nuclear receptors. The first studies linking nuclear receptors to EDCs focused on the reproductive defects caused by EDCs targeting estrogen and androgen signaling, through their cognate nuclear receptors. However, nuclear receptors form a large superfamily of transcription factors that play pivotal roles in integrating the Phthalate bound to PPARs create metabolic interference C Casals-Casas et al complexities of homeostasis and development. 22 All members of this superfamily have similar structural features with a DNA binding domain, which is the hallmark of this protein family, and a similar general fold of the ligand binding domain (LBD). Ligand binding causes conformational modifications that trigger a cascade of events, ending with the transcriptional activation of target genes. These events include the dissociation of corepressor protein complexes and association or recruitment of coactivator protein complexes, which then make the link to the basal transcription machinery. 23 Any lipophilic compound capable of specifically binding to these nuclear receptors can interfere with the corresponding endogenous ligand and the pathway it controls. Thus, the scope of molecular interference between EDCs and NRs, which initially focused on estrogen or androgen-like compounds, has been broadened to many other compounds. For instance, studies have shown that the di-n-butyl phthalate can activate the constitutive androstane receptor, the pregnane X receptor and the PPAR subtypes, all of which are nuclear receptors that regulate diverse metabolic pathways 6 and are highly expressed in the liver. Among the most often explored receptors are indeed pregnane X receptor, constitutive androstane receptor, aryl hydrocarbon receptor, and thyroid receptor. 24, 25 In addition to acting as direct agonist or antagonist compounds through binding to the nuclear receptor LBD, the mechanisms by which EDCs may interfere with NR pathways are likely multiple. For example, EDCs can affect the transcriptional activity of nuclear receptors by modulating proteasome-mediated degradation of nuclear receptors or their coregulators, [26] [27] [28] by inhibiting histone deacetylase activity or by triggering some of mitogen-activated protein kinase pathway activation processes. 2 Interestingly, the pesticide methoxychlore directly affects DNA methylation, and thereby causes transgenerational effects over four generations.
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PPARs: a target for metabolic disruptors Surprisingly, EDCs' interference with NRs implicated in metabolism has remained scarcely studied. In that respect, considering their strong implication in metabolic regulations and disorders as well as their ability to bind a diverse array of compounds, PPARs represent a very interesting target for EDCs. The PPAR family is composed of three isotypes (PPARa, -b, and -g), which play important roles in control of cellular differentiation programs and in the transcriptional control of lipid and carbohydrate metabolism. 30 They form heterodimers with the retinoid X receptor (RXR) and adopt an active conformation in the presence of an agonist. PPAR/RXR heterodimers bind to peroxisome proliferators response elements, a specific DNA sequence consisting in a direct repeat of AGGNCA separated by a single nucleotide (DR-1), present in the promoter region of PPAR-regulated genes. 31, 32 The LBD of PPARs is rather large and the diversity of ligands that can be accommodated within its pocket, mainly represented by lipid derivatives, may contribute to the large array of roles that have been assigned to PPARs. PPARa is mainly expressed in liver, cardiac and skeletal muscles, brown adipose tissue, kidney and intestine, and plays a key role in fatty acid catabolism. In contrast, PPARg is described as a 'thrifty gene' 33 because of its crucial function in adipocyte differentiation and lipid storage. 34 Finally,
PPARb is detected in all tested tissues where it plays very diverse roles, from cell differentiation and survival, to both systemic and tissue-specific fatty acid metabolism. [35] [36] [37] The fact that PPARs are implicated in pathways altered in metabolic disorders and the possibility to modulate their action through the binding of specific synthetic agonists have generated far-reaching pharmacological applications. More particularly, the hypolipidemic fibrates (acting through PPARa) and the insulin-sensitizing thiazolidinediones (acting through PPARg) are important therapeutic tools in the metabolic syndrome. As mentioned above, there is consistency between the large PPAR ligand binding pocket and the capacity to bind various compounds. Indeed, PPARa is a recognized target for pollutants as it mediates peroxisome proliferation and associated carcinogenic effects in rodent liver in response to a class of chemicals referred to as peroxisome proliferator chemicals. In addition, several reports have showed PPAR activation by environmental pollutants such as phthalates produced by the plastic industry, [38] [39] [40] perfluorooctane-based chemicals found in industrial surfactants, 41, 42 organotins used as agricultural fungicides and anti-fouling agents in ship paints, 13, 43 as well as several other pesticides. 44, 45 However, fairly little is known on the metabolic consequences of PPAR activation by pollutants, both in terms of molecular mechanism of action and physiological outputs.
PPARc and organotins: EDCs' effects on obesity
PPARg, as heterodimer with RXR, is a key player in energy storage and adipocyte differentiation. Therefore, a long-term PPARg activation by agonists, such as pharmaceutical therapies for type 2 diabetes, may promote weight gain as a side effect because of increased fat storage due to the induction of the 'thrifty gene response'. 33 In a recent study, Grün et al. 13 showed that organotins, such as Tributyltin chloride (TBT) and bis(triphenyltin) oxide, phenocopy the effects of PPARg and RXR ligands. Firstly, they describe in vitro that TBT, although structurally distinct from described ligands, binds to and activates the three human subtypes of RXR as well many permissive heterodimeric partners such as the liver X receptor, PPARb, nuclear receptor related-1 and PPARg, but not PPARa. Consistent with the critical role played by PPARg-RXR signaling in mammalian adipogenesis, TBT induced adipocyte differentiation by direct transcriptional effects on PPARg target genes. 13 The authors further showed that TBT is a Phthalate bound to PPARs create metabolic interference C Casals-Casas et al potential adipogenic agent in vivo that induces lipogenic PPARg-RXR target gene expression in liver and adipose tissue, and modulates factors associated with early adipocyte differentiation. Finally, they showed in mouse models that in utero exposure to TBT causes a disorganization of hepatic and gonadal architecture, some steatosis in liver, and an increase of lipid accumulation and mature adipocytes. Consistent with these results and with the Barker's hypothesis, the fat mass of in utero TBT-treated mice, but not the total body weight, is increased significantly at adulthood. In addition, ectopic adipocyte formation was observed in the Xenopus model, further supporting the conclusion that embryonic and chronic lifetime organotin exposure could play a role in the incidence of obesity by the disruption of the PPARg-RXR nuclear receptor pathway.
PPARc and phthalates: stepping in with the definition of a selective PPAR modulator
Like other structurally diverse chemicals including hypolipidemic drugs, endogenous steroids, herbicides and solvents, phthalates are recognized peroxisome proliferators in rodent models. 46 PPARa mediates the activity of these compounds on peroxisome proliferation and the long-term consequences on hepatocellular carcinoma development as showed by the lack of response of the PPARa null-mutant mice. 47, 48 This involvement of PPARs in the action of phthalate is consistent with the in vitro activation of PPARa, but also PPARb and PPARg using transactivation assays and intact cellular systems with endogenous receptors and target genes. 38, 39 These studies determined the range of potency and efficacy of phthalate monoesters on PPARa, PPARb and PPARg activation. They also showed that mouse PPARa and PPARb are generally activated at relatively lower concentrations of phthalate monoesters than human PPARa and PPARb, whereas human and mouse PPARg exhibit similar sensitivity. In parallel, interaction of some phthalate metabolites with PPARa are responsible for in vivo effects, such as malformations in the male reproductive tract and liver cancer in mice and rats. 40, 49, 50 Amazingly, fairly little is known on the metabolic consequences of phthalate exposure. Therefore, we addressed the issue of interference of EDCs with PPARregulated processes using the MEHP metabolite of the DEHP plasticizer as a model. 51 Indeed, our first observation was that MEHP acts similarly to rosiglitazone, a specific PPARg agonist, and promotes 3T3-L1 adipogenesis although the maximal effect of MEHP remains lower than that induced by Rosiglitazone. 51 These effects of MEHP on adipocyte differentiation were truly mediated by PPARg as showed by silencing PPARg and by using specific inhibitors of PPARg.
A recently developed concept, more particularly used in the context of PPARg agonist activity is that of selective nuclear receptor modulator. Selective estrogen receptor modulators were the first selective modulators to be described, owing to the tissue-specific activity of Tamoxifen, which is an anti-estrogen in breast but behaves as an estrogen receptor agonist in bone or in the cardiovascular system. The proposed molecular bases are the following. A given ligand can induce a specific conformational change of the receptor, which allows the recruitment of only a subset of coregulators. This subset of coregulators will dictate the binding to only a subset of target genes. Finally, the activation of a subset of genes will translate into a partial or specific physiological response. The concept of 'selective PPARg modulators' (SPPARgM) has emerged with the idea to modulate the metabolic genes that are both necessary and sufficient to achieve insulin sensitization, while not affecting the genes involved in fat accretion or prompting other side effects (for example, edema). 52 Discovering the ability of MEHP to interfere with PPARg activity at different levels than full agonists, we thus checked whether MEHP could act as a PPAR modulator with selective metabolic activities.
In a first step, we corroborated by transactivation assays that MEHP activates mouse PPARs, albeit to a lower extent than the reference agonist. [38] [39] [40] MEHP can indeed activate all mouse and human PPARg isoforms, even though with different efficacies between isoforms and cell lines. The next step was to evaluate the binding mode of MEHP in the PPARg LBD. The modeling was based on the earliersolved crystallographic structure of PPARg LBD with rosiglitazone in its pocket. [53] [54] [55] Intriguingly, MEHP and rosiglitazone have similar binding patterns and interacting contacts in the PPARg LBD. 51, 56 Thus, the different affinities and efficacies between the two compounds could be because of subtle variations. We next studied how MEHP modulates the recruitment and release of coregulators. Considering the complexity of protein-protein interactions occurring in vivo and the limits of the in vitro tools, microscopy techniques are good alternatives for the analysis of these interactions in the living cells. Fluorescence correlation spectroscopy is a technique measuring the diffusion of fluorescent molecules at high temporal resolution and allows measurements of the mobility of proteins or complexes, which varies according to the mass of the complex. Hence, the formation of large complexes through coactivator recruitment reduces the rate of diffusion and different patterns of mobility should correlate with the formation of different complexes. We first showed that the fusion protein YFP-PPAR exhibits a reduced mobility on ligand binding consistent with enhanced coactivator recruitment in response to ligand binding. [57] [58] [59] Accordingly, exposure to MEHP or rosiglitazone induced a reduction of PPARg mobility, but the smaller reduction obtained with MEHP 51 suggested that MEHP binding promotes the formation of smaller and thus different complexes than those formed in response to rosiglitazone. To define the specific coregulators recruited or released by MEHP or rosiglitazone in the context of a living cell, we used fluorescence resonance energy transfer imaging, a technique that allows the monitoring of protein interactions. Fluorescence resonance energy transfer is a method Phthalate bound to PPARs create metabolic interference C Casals-Casas et al based on the nonradiative transfer of energy between a donor and an acceptor fluorophore with overlapping respective spectra of emission and excitation. 60, 61 Interactions are generally detected if the distance between fluorophores does not exceed 5-10 nm, a proximity only allowed by a direct interaction of the two partners. 62, 63 After establishment of the appropriate tools for fluorescence resonance energy transfer imaging, we showed that MEHP only partially abolishes the strong interaction between PPARg and the corepressor NCoR, as compared with the strong release obtained with rosiglitazone. Whereas the recruitment of the coactivator Med1 was similar between the two compounds, only rosiglitazone efficiently recruited p300, whereas MEHP allowed a much better recruitment of the PPARg coactivator 1 a 51 ( Figure 1 ). These results obtained in vitro were further confirmed by chromatin immunoprecipitation analysis, with which we analyzed the occupancy pattern of coregulators on specific promoters of PPARg target genes. Altogether, these mechanistic studies show that MEHP, acts like a SPPARM at the molecular level and induces a selective recruitment of PPARg coregulators.
In the last step, we consequently showed that, while both MEHP and rosiglitazone strongly affect genes implicated in metabolism and cell cycle as well as genes required for the structure of lipid droplets and the function of mature adipocytes, MEHP induces the activation of only a subset of PPARg target genes, with the first set consisting of genes that are less activated by MEHP than by rosiglitazone during the whole differentiation process, like Gyk, Olr1 and Acsbg1, whereas the second group, which includes Fabp-4, is equally induced by MEHP and rosiglitazone during differentiation 51 ( Figure 1) . Hence, the phthalate monoester MEHP is proadipogenic in a cell culture model, suggesting that this subclass of EDCs should be defined as 'metabolic disruptors'. We also deciphered the molecular mechanism of action, showing that MEHP acts as a SPPARM, 52 studies of which remain an important target for pharmaceutical research on type 2 diabetes.
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Assessment of metabolic effects upon in utero and perinatal exposure to phthalates
On the basis of similar adipogenic activity of phthalates and organotins, 13 we reasoned that phthalates could have actions on adipogenesis and fat accretion in vivo. Earlier studies have indeed shown that both in utero and adult exposure to phthalates have various effects on endocrine functions, in some cases mediated by PPARs. 17, 19, 40, 49, 66 Embryogenesis is a very sensitive period and several studies Figure 1 Schematic representation of the effects of MEHP on adipogenesis through selective PPARg modulation. MEHP, compared to the specific PPARg agonist rosiglitazone, only partially abolishes the interaction between PPARg and the corepressor NCoR. With respect to coactivators, MEHP is totally inefficient in inducing the recruitment of SRC-1 and p300, but promotes the recruitment of Med1at lower levels than rosiglitazone and enhances the interaction with PGC-1a at stronger levels than rosiglitazone. Through this selective recruitment of regulators, MEHP regulates only a subset of PPARg target genes compared with the full agonist. Two groups of genes can be distinguished. Gyk, Olr1 and Acsbg1 on which MEHP exerts a lower activity than rosiglitazone exemplify the group 1. In contrast, group 2 includes Fabp-4 and Adipoq as examples of genes, which equally respond to MEHP and rosiglitazone. This differential gene regulation of MEHP compared to rosiglitazone leads to a lower, even if significant, induction of adipogenesis. PGC-1a, PPARg coactivator 1 a; MEHP, mono(2-ethylhexyl)phthalate; PPAR, peroxisome proliferator-activated receptors.
Phthalate bound to PPARs create metabolic interference C Casals-Casas et al showed a correlation between in utero EDC exposure and metabolic disorders developed at adulthood. 9 We thus used mouse models to test the effects of in utero exposure to DEHP, the compound most relevant to human exposure, which is metabolized into the PPAR activator MEHP. For this purpose, we studied offspring from untreated parents, from males treated with DEHP before breeding (treated fathers) or from females treated with DEHP during gestation and lactation ( Figure 2 ). As we designed our experiment as a proof of concept, the parents were treated with a relatively high dose of DEHP (200 mg per kg of body weight per day) shown to be active earlier on PPAR signaling at the gene expression level. The weight gain monitored from weaning to adulthood, and animals were subsequently challenged with high-fat feeding to induce obesity. The growth and the development of obesity of mice from treated fathers or treated mothers were similar to that of mice from untreated parents. Other parameters such as liver weight, brown and white adipose tissue weights and the levels of blood glucose were not affected by parental treatment either (Figure 2) . Thus, although in utero or prenatal phthalate exposure can cause sexual and developmental disorders, [67] [68] [69] it seems unlikely from our results that developmental exposure to the most abundant phthalate plasticizer, DEHP, causes metabolic disorders at adulthood. However, more extensive studies will be required, more particularly with aging mice and with different doses and different phthalate esters, to totally rule out adverse effects of phthalates on metabolic function following in utero exposure.
As metabolic disorders are multifactorial diseases to which genetic and epigenetic factors contribute only partially, it remains of great importance to understand the direct actions of phthalates on metabolic homeostasis in adults. Towards that goal, experiments evaluating the metabolic conse- Figure 2 Actions of trans-generational and in utero DEHP exposure on metabolic homeostasis. (a) Experimental protocol: male and female C57Bl6/J mice were fed during 3 weeks with a regular chow diet supplemented either with vehicle (sunflower oil) or DEHP at a concentration leading to an average exposure of 200 mg per kg of body weight per day. These animals were then bred to generate offsprings where the transgenerational and in utero effects of DEHP could be evaluated. In control breedings, both males and females were untreated, and generated siblings labeled 'untreated parents'. In contrast, two other groups of animals resulted from breedings between untreated females and males exposed to DEHP before breeding (treated fathers) or untreated males and females exposed to DEHP before breeding and during gestation and lactation (treated mothers). The resulting animals were maintained on chow diet for 4 weeks from weaning to adulthood and then challenged by high-fat feeding for 12 weeks. (b) Metabolic parameters were analyzed in 3-week-old animals with untreated parents (black bars), treated fathers (dark gray bars) and treated mothers (light gray bars) (n ¼ 8 per group). (c) Growth curves on chow and high-fat diet of animals with untreated parents, treated fathers and treated mothers (n ¼ 8 per group). DEHP, di-ethyl-hexyl-phthalate.
Phthalate bound to PPARs create metabolic interference C Casals-Casas et al quences of adult exposure to DEHP in mouse models are in progress in our laboratory. As phthalates can activate the three PPARs (a, b and g), which regulate a systemic balance between energy storage and expenditure, the actions of DEHP will most likely integrate the physiological cooperation between these three nuclear receptors across multiple metabolic organs.
Conclusion
In the last decades, several new xenobiotics with endocrine disruption properties have emerged. Phthalates, organotins and other EDCs are used worldwide and have become ubiquitously present in the environment as well as in humans and animals. Altogether, a number of recent studies define the concept of metabolic disruptors through which environmental pollutants can exert adverse effects on metabolic homeostasis. Importantly, over the past three decades, the correlation between the increased use of several industrial compounds and the increased rates of metabolic disorders has led to speculation that a causal link could exist. The combination of more human toxicological and epidemiological studies to experiments in cell and animal models, which allow one to rigorously control for environmental factors and to decipher the mechanisms underlying the effects observed, will definitely be required to understand the exact incidence of metabolic disruptors on human health. Most of the works presented herein focus on the effects of individual compounds. However, the environment is composed of a mixture of different EDCs and future studies must address the 'cocktail effect' that may result in synergistic or additive effects. Altogether, we strongly believe that it is extremely important to objectively analyze the concerns raised by EDCs on all aspects of human physiology. The 'classical' animal toxicology of individual compounds is definitely of high importance but needs to be complemented by epidemiological analyses at the level of entire populations and by mechanistic approaches that give credibility to the alarms sent by the scientific community, and give means for balanced environmental and political regulations.
